Japanese traditional dietary fungus koji *Aspergillus oryzae* functions as a prebiotic for *Blautia coccoides* through glycosylceramide: Japanese dietary fungus koji is a new prebiotic

Hiroshi Hamajima¹†, Haruka Matsunaga¹†, Ayami Fujikawa¹†, Tomoya Sato¹, Susumu Mitsutake², Teruyoshi Yanagita³, Koji Nagao², Jiro Nakayama³ and Hiroshi Kitagaki¹*

**Abstract**

**Background:** The Japanese traditional cuisine, Washoku, considered to be responsible for increased longevity among the Japanese, comprises various foods fermented with the non-pathogenic fungus *Aspergillus oryzae* (koji). We have recently revealed that koji contains an abundant amount of glycosylceramide. Intestinal microbes have significant effect on health. However, the effects of koji glycosylceramide on intestinal microbes have not been studied.

**Materials and methods:** Glycosylceramide was extracted and purified from koji. C57BL/6N mice were fed a diet containing 1% purified koji glycosylceramide for 1 week. Nutritional parameters and faecal lipid constituents were analyzed. The intestinal microbial flora of mice on this diet was investigated.

**Results:** Ingested koji glycosylceramide was neither digested by intestinal enzymes nor was it detected in the faeces, suggesting that koji glycosylceramide was digested by the intestinal microbial flora. Intestinal microbial flora that digested koji glycosylceramide had an increased ratio of *Blautia coccoides*. Stimulation of *B. coccoides* growth by pure koji glycosylceramide was confirmed in vitro.

**Conclusions:** Koji functions as a prebiotic for *B. coccoides* through glycosylceramide. Since there are many reports of the effects of *B. coccoides* on health, an increase in intestinal *B. coccoides* by koji glycosylceramide might be the connection between Japanese cuisine, intestinal microbial flora, and longevity.

**Keywords:** Japanese cuisine, Koji, Glycosylceramide, Intestinal microbial flora, *Blautia*, *Aspergillus*, Prebiotic

**Background**

The Japanese traditional cuisine Washoku was recently registered by UNESCO as an intangible cultural heritage (United Nations Educational, Scientific and Cultural Organization 2013). A number of mechanisms linking Japanese cuisine to its health effects have been proposed, such as the preponderance of low saturated fatty acids, high fibre, and omega-3 polyunsaturated fatty acids. However, some unknown factors besides nutritional components such as protein, fat, carbohydrate balance, or dietary fibre are considered to influence the longevity of the Japanese (Yamamoto et al. 2016); a concrete mechanism linking Japanese cuisine and its health effects remains to be elucidated.

One common characteristic of Japanese cuisine is that it contains various and abundant fermented foods. Most Japanese fermented foods contain koji (rice fermented with the non-pathogenic fungus *Aspergillus oryzae* or *A. luchuensis* (Machida et al. 2005)) as the saccharifying agent of the starch contained in crops (Kitagaki and Kitamoto 2013). These include miso (soybean and barley fermented with koji), shoyu (soy sauce), amazake...
(rice koji beverage), osu (rice vinegar), kurosu (black rice vinegar), sake (alcoholic beverage fermented with koji), and shochu (distilled alcoholic beverage fermented with koji). Food manufactured using fungi as the saccharifier is found in countries in the east and southeast regions of Asia, such as Korean makgeolli, Chinese huangjiu, and Indonesian tempe. Since the Japanese traditional dietary fungus *A. oryzae* has been bred and maintained as a safe and non-mycotoxin-producing fungus (Machida et al. 2005) and used in the food culture in Japan (Murakami 1985) for centuries, the US Food and Drug Administration (FDA) recognizes koji as generally regarded as safe (GRAS) and the Brewing Society of Japan lists the koji-producing fungi, *A. oryzae* and *A. luchuensis*, as the “national fungi” of Japan. However, few studies report the functionalities of eating koji. One possible explanation is the fact that *Aspergillus* mycelia contain β-glucan (Ishibashi et al. 2004), which activates macrophages through Dectin-1 (Brown and Gordon 2001) and improves glycaemic index (Jenkins et al. 2002) and serum cholesterol (Wang et al. 2016). However, the nutritional benefit of eating koji or *A. oryzae* has not been studied.

In earlier studies, we have elucidated that koji contains abundant glycosylceramide (0.5–3 mg/g dry weight) (Hirata et al. 2012; Takahashi et al. 2014; Sawada et al. 2015), which is one of the highest amounts found in any cuisine. Glycosylceramide is composed of a sugar moiety, fatty acid moiety, and sphingoid base moiety, and is categorized as a sphingolipid. Sphingolipids are critical components of the cell membrane and exert various biological functions (Truman et al. 2014; Russo et al. 2013). Koji glycosylceramide consists of N-2′-hydroxyoctadecanoyl-l-O-β-D-glucopyranosyl-9-methyl-4,8-sphingadienine (69.7 %) and N-2′-hydroxyoctadecanoyl-l-O-β-D-galactopyranosyl-9-methyl-4,8-sphingadienine (30.3 %) (Hamajima et al. 2016). These chemical structures differ from those in other species and the Japanese have consumed koji glycosylceramide for centuries, with current consumption being 25.7–77.1 mg glycosylceramide per day (Yunoki et al. 2008). Koji glycosylceramide might exert unique effects that could contribute to the health benefits of Japanese cuisine.

Intestinal microbial flora has a great impact on health (Fukuda et al. 2011; Sommer and Bäckhed 2013; Kanauchi et al. 2013), and many diseases are reported to be related to intestinal microbial flora (Round and Mazmanian 2009; Hold 2016; Benakis et al. 2016; Del Chierico et al. 2016). Interestingly, great variations in intestinal microbial flora among several ethnic groups are observed (De Filippo et al. 2010; Moeller et al. 2014; Nakayama et al. 2015). Thus, food content is considered to affect the intestinal microbial flora, which might provide a new therapeutic strategy for diseases. However, the relationship between Japanese food and intestinal microbial flora remains unknown.

In this study, we hypothesized that koji glycosylceramide alters the intestinal microbial flora. Specifically, that koji glycosylceramide increases the content of several microbes, including *Blautia cocoides*. Since *B. cocoides* is reported to have several health benefits, an increase of *B. cocoides* through the intake of koji glycosylceramide might be one mechanism explaining Japanese longevity. This knowledge can be utilized to improve the nutritional content of foods of other nations and increase life expectancy around the world.

**Methods**

**Materials**

Pre-gelatinized dried koji (rice polishing ratio 70 % w/w fermented with *A. oryzae*) was purchased from Tokushima Seikiku Co., Ltd (Tokushima, Japan).

**Bacterial strains**

*Blautia cocoides* (ATCC® 29236; ATCC, VA, USA), *Escherichia coli* (New England Biolabs, MA, USA) and *Lactobacillus casei* (Saga University) were used in this study.

**Lipid extraction and purification**

Lipid extraction from koji was performed as described earlier (Hirata et al. 2012; Takahashi et al. 2014). The lipid was extracted from 1.8 kg koji by chloroform–methanol (2:1, v/v) at a concentration of 100 mg/mL. The extracted lipid solution (10 mL) was dried by evaporator, and the dried lipids were dissolved in 5 mL of chloroform. This chloroform solution was incubated at 4 °C for 1 h and the precipitate was filtered and removed. The solution was evaporated and dissolved in chloroform–methanol (2:1, v/v) at a concentration of 100 mg/mL. The precipitate was dissolved in chloroform–methanol (2:1, v/v) as above. The solution (5 mL) was dried by evaporator and dissolved in 5 mL of acetone. This acetone solution was incubated on ice for 1 h and the precipitate and supernatant were separated by centrifugation. The precipitate was washed with cold acetone twice. The recovered supernatant and the washed acetone fraction were dried by evaporator. The dried sample was dissolved in chloroform–methanol (2:1, v/v) at a concentration of 100 mg/mL and used as the purified koji glycosylceramide in further analyses.

**Animals and diets**

All aspects of the experiments were conducted according to the guidelines provided by the ethical committee for experimental animal care at Saga University. Five-week-old male C57BL/6N mice were purchased from Kyudo Co., Ltd. (Saga, Japan). The mice were individually
housed in plastic cages in a temperature-controlled room (24 °C) under a 12 h light/dark cycle. The basal semisynthetic diets were prepared according to the recommendations of the AIN-76 (Shirouchi et al. 2007) (Table 1). Koji glycosylceramide was extracted and purified as above, and the general components of the samples were routinely determined according to official AOAC methods. The mice were assigned to two groups (three mice each) that were fed one of two diets (Table 1), a semisynthetic AIN-76 diet (Control group) or a semisynthetic AIN-76 diet supplemented with 1 % purified koji glycosylceramide. The mice received the diets ad libitum using Rodent CAFE (KBT Oriental Co., Ltd., Saga, Japan) for 1 week. At the end of the feeding period, the mice were sacrificed by exsanguination from the heart under isoflurane anaesthesia following a 9 h starvation period. Kidneys, adrenal glands, perirenal white adipose tissue, spleens, appendix, brains, and livers were excised immediately, and the serum was separated from the blood.

Analysis of hepatic lipids and serum parameters
Liver lipids were extracted according to the method of Folch et al. (1957), and the concentrations of triglycerides, cholesterols, and phospholipids were measured using the methods of Fletcher (1968), Sperry and Webb (1950), and Rouser et al. (1966), respectively. The triacylglycerol, cholesterol, phospholipid, and glucose levels in the serum were measured using enzyme assay kits from Wako Pure Chemicals (Tokyo, Japan).

Analysis of intestinal microbial flora
Faecal samples were freeze-dried for 3 days, and genomic DNA was extracted from the faecal samples using the bead-beating method as described previously (Matsuki et al. 2004). The region containing the 16S rRNA V3–V4 variable region was amplified by PCR according to the Illumina protocol (Illumina Inc. 2013), and the sequences were analyzed using Miseq (Illumina, Inc., CA, USA). The Miseq Reporter 16S metagenomics system was used to obtain the information on the bacterial composition. The microbial cluster tree was categorized using the NCBI taxonomy browser (MD, USA).

In vitro analysis of the effect of koji glycosylceramide on microbial growth
Blautia coccoides was inoculated in yeast-peptone-dextrose (Becton, Dickinson and Company, NJ, USA) medium containing sodium cholate (0.0015 % v/v) and glucosylceramide (4 μg/μL in ethanol) or vector ethanol (1 % v/v) at a cell density of 1 × 10^6 cells/mL. The bacterial cells were incubated in anaerobic jars (AnaeroPack Kenki, Mitsubishi Gas Chemical Co., Inc., Tokyo, Japan) at 30 °C for 24 h. Cultures were homogenized and the OD_{600} was measured using a spectrophotometer (UV-1800; Shimadzu, Kyoto, Japan). To incubate Lactobacillus casei, MRS medium (Becton, Dickinson and Company) was used; to incubate Escherichia coli, Luria-Bertani (LB) medium (Nissui, Tokyo, Japan) was used.

Preparation of intestinal extracts
Fresh mouse small intestine was thoroughly washed with washing buffer (50 mM Tris-HCl buffer pH 7.5, 150 mM NaCl). The small intestine was cut into small pieces and collected in a clean plastic tube. The collected fragments of small intestine were homogenized with the Polytron 10/35 (Kinematica Inc., Luzern, Switzerland) in homogenization buffer (50 mM Tris-HCl buffer pH 7.5, 150 mM NaCl, protease inhibitor cocktail set V, and 1 mM phenylmethylsulfonyl fluoride; Wako Pure Chemicals, Tokyo, Japan). The homogenate was centrifuged at 500 × g for 5 min to remove debris. The protein concentration of the supernatant was determined using a DC protein assay (Bio-rad Laboratories, Inc., CA, USA).

Activity assay of intestinal enzymes
The purified koji glycosylceramide (0.5 or 1.0 mg) was dissolved in reaction buffer (50 mM Tris-HCl buffer pH 7.5, 0.5 % w/v Triton X-100). Intestinal extract corresponding to 2 mg protein diluted twofold with pure water was added to the solution. The reaction solution was incubated at 37 °C for 18 h or 30 h. The reaction was stopped by boiling for 5 min, and then the solution was freeze-dried. The samples were dissolved in chloroform–methanol (2:1, v/v) and applied to TLC analysis. TLC was developed with chloroform–methanol–acetic acid–water (20:3.5:2.3:0.7, v/v). Detection was performed with 2 mg/mL orcinol in 70 % H₂SO₄ reagent. Ceramidase activity was measured using C12-NBD-ceramide (Avanti Polar

### Table 1 Composition of experimental diets

|          | Nor  | Kgc  |
|----------|------|------|
| Casein   | 20.0 | 20.0 |
| Corn starch | 15.0 | 15.0 |
| Cellulose | 5.0  | 5.0  |
| Mineral mixture^a | 3.5  | 3.5  |
| Vitamin mixture^a | 1.0  | 1.0  |
| α-Methionine | 0.3  | 0.3  |
| Choline bitartrate | 0.2  | 0.2  |
| Corn oil  | 7.0  | 7.0  |
| Purified koji glycosylceramide | –    | 1.0  |
| Sucrose   | 48.0 | 47.0 |

Nor = control and Kgc = koji-supplemented diet

^a AIN-76
Lipids, Inc., AL, USA) as the substrate (Mitsutake et al. 2001). C12-NBD-ceramide (1 nmol) was incubated at 37 °C for 18 h with 0.5 mg of the intestine extract. Chloroform–methanol (2:1, v/v) was added to the reaction mixture, the lower phase was collected and applied to a TLC analysis plate and developed with chloroform–methanol–25 % ammonia (90:20:0.5, v/v) and visualized by fluorescence.

Results
Extraction and purification of koji glycosylceramide
First, glycosylceramide was extracted and purified from 1.8 kg koji. Lipids were extracted with chloroform–methanol, and ester-linked lipids were degraded by mild alkaline treatment. Glycosylceramide was further purified with chloroform–acetone fractionation (Fig. 1a, b). Table 2 shows the result of purification of glycosylceramide from 1.0 g koji. Finally, 2.8 g of koji glycosylceramide was purified as a major band containing two minor bands (Fig. 1b).

Feeding of koji glycosylceramide
Purified koji glycosylceramide was fed to mice for 1 week (Table 2). Although the changes were not statistically significant (p > 0.05), the levels of serum and liver triglycerides increased while those of serum glucose and liver cholesterol decreased (Table 3). Additionally, the relative weight of the adrenal gland increased while the relative weight of the perirenal white adipose tissue decreased (Table 4). These results suggest that fed glycosylceramide was metabolized to triglyceride in the intestine and appears to play a role in decreasing serum glucose levels while increasing the relative weight of the adrenal gland. The precise meaning of these changes awaits further analysis.

Table 2 Purification summary of glycosylceramide from koji

| Koji lipid | Chloroform | Acetone |
|-----------|------------|---------|
|           | Soluble fraction | Insoluble fraction | Insoluble fraction | Soluble fraction |
| Weight of total recovery | 0.39 g ± 0.01 | 0.59 g ± 0.01 | 0.25 g ± 0.04 | 0.24 g ± 0.06 |
| Weight of glycosylceramide | 24.49 mg ± 2.49 | 0.17 mg ± 0.02 | 22.24 mg ± 0.84 | 17.80 mg ± 1.63 | 3.64 mg ± 2.36 |
| Purification rate of glycosylceramide | 2.46 % ± 0.21 | 0.04 % ± 0.00 | 3.79 % ± 0.18 | 7.28 % ± 0.59 | 1.41 % ± 0.56 |

Summary of glycosylceramide purification from 1 g of koji lipid. Glycosylceramide was purified from koji by chloroform–acetone fractionation. The results are expressed as mean values ± standard deviation of three independent experiments.

Metabolic fate of koji glycosylceramide during passage through the intestine
A previous study indicated that 40.8–45.8 % of the fed 3H-labelled sphingosine portion of glycosylceramide purified from beef brain is recovered in faeces (Nilsson 1969). However, since koji glycosylceramide differs from bovine glycosylceramide in structure, the lipid profile of the faeces from mice fed with koji glycosylceramide was analyzed in order to investigate its metabolic fate during passage through the intestine. No clear band of glycosylceramide was detected (Fig. 2a), and ceramide or sphingoid bases were also not detected (data not shown) in the faeces. Considering that koji apparently contains only glycosylceramide, these results suggest that ingested koji glycosylceramide is metabolized or absorbed in...
Table 3 Effect of koji glycosylceramide on serum and hepatic parameters in mice

|                  | Nor      | Kgc      |
|------------------|----------|----------|
| Serum            |          |          |
| Cholesterol (mg/dL) | 101 ± 2  | 96.0 ± 1.4 |
| Triglyceride (mg/dL) | 67.6 ± 0.7 | 104 ± 14  |
| Phospholipid (mg/dL) | 207 ± 1  | 213 ± 7  |
| Glucose (mg/dL)   | 248 ± 2  | 224 ± 7  |
| Liver            |          |          |
| Cholesterol (mg/g liver) | 3.03 ± 0.05 | 2.60 ± 0.16 |
| Triglyceride (mg/g liver) | 23.6 ± 5.0  | 26.3 ± 4.5 |
| Phospholipid (mg/g liver) | 33.4 ± 5.1  | 30.0 ± 1.1 |

*Nor* = control and *Kgc* = koji-supplemented diet

Table 4 Effects of koji glycosylceramide on growth parameters in mice

|                   | Nor      | Kgc      |
|-------------------|----------|----------|
| Initial body weight (g) | 18.9 ± 0.6 | 18.9 ± 0.5  |
| Final body weight (g)  | 20.0 ± 0.7 | 19.8 ± 0.3  |
| Body weight gain (g)   | 1.13 ± 0.16 | 0.900 ± 0.208 |
| Food intake (g)        | 19.2 ± 1.0  | 20.4 ± 1.1  |
| Food efficiency (g)    | 0.0603 ± 0.0122 | 0.0441 ± 0.0098 |
| Liver (g/100 g B.W.)    | 5.78 ± 0.08  | 6.44 ± 0.18  |
| Kidney (g/100 g B.W.)   | 1.33 ± 0.05  | 1.38 ± 0.01  |
| Adrenal gland (g/100 g B.W.) | 0.0216 ± 0.009 | 0.0352 ± 0.0101 |
| Perirenal white adipose tissue (g/100 g B.W.) | 0.605 ± 0.052 | 0.424 ± 0.058 |
| Spleen (g/100 g B.W.)   | 0.277 ± 0.021 | 0.289 ± 0.014 |
| Appendix (g/100 g B.W.) | 0.977 ± 0.063 | 1.14 ± 0.05  |
| Brain (g/100 g B.W.)    | 2.01 ± 0.12  | 2.06 ± 0.08  |

B.W.: Body Weight

*Nor* = control and *Kgc* = koji-supplemented diet

the intestine either by intestinal enzymes or intestinal microbes.

**Koji glycosylceramide is not degraded by intestinal extract**

The above results inspired us to hypothesize that koji glycosylceramide is digested in the upper intestine by intestinal enzymes. To prove this hypothesis, intestines were recovered from mice, homogenized, and incubated with koji glycosylceramide. Lipid profiles of koji glycosylceramide treated with the intestinal extract and untreated koji glycosylceramide were not significantly different (Fig. 2b). On the contrary, the intestinal enzymes had the ability to digest NBD-C12-ceramide (Fig. 2c). These results indicate that intestinal enzymes have the ability to degrade ceramide but not koji glycosylceramide; thus, koji glycosylceramide reaches the lower intestine where it is then metabolized by intestinal microbial flora.

**Identification of Blautia coccoides as the intestinal microbe that increases in number upon ingestion of koji glycosylceramide**

The results above suggested that koji glycosylceramide reaches the lower intestine and affects intestinal microbial flora. Therefore, in order to analyze the intestinal microbial flora, genomic DNA was extracted from the faeces of koji glycosylceramide-fed or non-fed mice. It turned out that *B. coccoides*, *Dorea*, *Clostridium alkalicellulosi*, *Hathewaya histolytica*, *Bacteroides sartorii*, *Dysgonomonas*, *Dysgonomonas wimpennyi*, *Alphaproteobacteria*, *Chromatiales*, and *Chloroflexi* significantly increased in response to the addition of koji glycosylceramide (*p < 0.05*, Fig. 3a). *B. coccoides* is a strict anaerobe, which is often found in the mammalian intestine (Park et al. 2013).

**In vitro stimulation of the growth of Blautia coccoides by koji glycosylceramide**

The above feeding experiments were based on glycosylceramide purified from koji. However, the purification of glycosylceramide was not complete (Fig. 1b), thus it was not clear if pure glycosylceramide would stimulate the growth of these bacteria. However, preparation of 2.8 g of pure koji glycosylceramide was difficult. Therefore, investigation of stimulation of bacterial growth by koji glycosylceramide was conducted in vitro. Since *B. coccoides* is attracting greater attention because of its effects on health, we focused on *B. coccoides*. Bacteria were incubated with purified glycosylceramide and the growth was monitored. Consistent with our hypothesis, the growth of *B. coccoides* was stimulated with either koji glycosylceramide (Fig. 4a) or soy glucosylceramide (Fig. 4b). On the contrary, glycosylceramide did not affect the growth of general intestinal microbes such as *Escherichia coli* (Fig. 4c) or *Lactobacillus casei* (Fig. 4d). These results support our hypothesis that koji glycosylceramide specifically stimulates the growth of *B. coccoides* in the intestine.

**Discussion**

Although the Japanese people have eaten Japanese cuisine on a national level for centuries and presently have one of the longest healthy life spans in the world, the relationship between Japanese cuisine and Japanese longevity has remained obscure. In this study, we elucidate that koji glycosylceramide modulates intestinal microbial flora, specifically by increasing *B. coccoides*. This mechanism...
might be a new connection between Japanese cuisine and Japanese longevity.

*Blautia coccoides* is one of the major intestinal microbes often found in human faecal samples (Park et al. 2013). It is a strict anaerobe and gram-positive bacteria recently reclassified from *Clostridium* (Liu et al. 2008). There are growing reports of the relationship between decreased levels of *B. coccoides* and disease, such as cirrhosis and hepatic encephalopathy (Bajaj et al. 2012), colorectal cancer (Chen et al. 2012), intestinal inflammation (Jenq et al. 2012), type 1 diabetes (Murri et al. 2013), irritable bowel syndrome (Rajilić-Stojanović et al. 2011), acute diarrhoea, and idiopathic inflammatory bowel disease (Suchodolski et al. 2012). Furthermore, several reports suggest that increasing the ratio of *B. coccoides* in the intestine might be beneficial for health. Indeed, diets high in resistant starch and arabinoxylan increase the ratio of *B. coccoides* in the intestinal microbial flora (Nielsen et al. 2014), as do omega 3 fatty acids (Myles et al. 2014). In addition, *B. coccoides* decreases the NF-κB activity in Caco-2 cells (Lakhdari et al. 2011; Jenkins et al. 2002). *B. coccoides* does not evoke an inflammatory response in mononuclear cells (Tuovinen et al. 2013). Therefore, there is evidence that intestinal *B. coccoides* contributes to health.

The modification of intestinal *B. coccoides* by Japanese cuisine and its effect on health is of significant concern. Several studies point out that changes in the intestinal population levels of the genus *Blautia* are dependent on the diet, age or nationality. Indeed, the genus *Blautia* was most frequently found in the faeces of Japanese people (Nishijima et al. 2016) relative to other nations in the world, supporting the hypothesis that Japanese cuisine containing koji increases *B. coccoides* in the intestine. Intestinal population levels of *Blautia* in children with type 1 diabetes are significantly higher than those in healthy children (Murri et al. 2013). In addition, the population level of *Blautia* is decreased in the intestines of cirrhotic patients (Kakihama et al. 2013), as well as in elderly people relative to young people (Kurakawa et al. 2015). Together with the knowledge attained in this study, it is likely that Japanese people have increased levels of intestinal *B. coccoides* through consumption of koji glycosylceramide contained in the Japanese cuisine,

---

**Fig. 2** Metabolic fate of koji glycosylceramide in the intestine. 

- **a** Total lipid profile of feces from mice fed with or without koji glycosylceramide. Nor indicates the feces of non-added mice and Kgc indicates those of koji glycosylceramide-fed mice. The number indicates the replicate number of experiments. 
- **b** Total lipid profile of koji glycosylceramide incubated with intestinal extracts. 
- **c** NBD-TLC of C12-ceramide incubated with intestinal extracts, developed, and visualized by orcinol–H2SO4 reagent or fluorescence. SG indicates Sterylglucoside and GlcCer indicates glycosylceramide, a and b indicate hydroxylated and nonhydroxylated cerebroside respectively.
contributing to the health status of the Japanese people (Symolon et al. 2004; Fujiwara et al. 2011; Yazama et al. 2015). This hypothesis needs further study and verification.

The practical effect of koji glycosylceramide in the daily intake of Japanese traditional cuisine can be inferred from this study. In this study, mice (19.8 g weight) ate 20.4 g per week, which corresponds to 0.147–0.294 (g/}
day)/(g body weight). Since koji glycosylceramide was present in the feed at 0.2–1 % w/w, this corresponds to 0.71–1.43 g/day for a 60 kg human [human equivalent doses (Reagan-Shaw et al. 2008)]. Considering that Japanese people eat 5–100 g koji per day and koji contains 0.5–3 mg/g glycosylceramide, Japanese people intake 0.0025–0.3 g koji glycosylceramide per day. Therefore, the doses used in this study can be considered sufficiently effective in humans.

Previous studies provide sufficient evidence that dietary glycosylceramide is digested and absorbed in the intestine (Nilsson 1969; Schmelz et al. 1994). Therefore, since intestinal enzymes cannot degrade glycosylceramide (Fig. 2b), intestinal microbes are considered to have the ability to degrade glycosylceramide to ceramide. Consistent with this hypothesis, intestinal Blautia glucerasi was shown to degrade glycosylceramide to ceramide (Furuya et al. 2010). From these facts, it appears that these microbes degrade koji glycosylceramide to ceramide, and the resulting sugar moiety and ceramide are metabolized to fatty acids and sphingoid bases, which are then absorbed in the intestine (Nilsson 1969). This is a significant target of the next study.

Several studies reported that dietary soy or rice bran glucosylceramide reduces cancers such as colon cancer and head and neck cancer (Symolon et al. 2004; Fujisawa et al. 2011; Yazama et al. 2015). In addition, plant-origin glucosylceramide suppresses bowel inflammation (Arai et al. 2015). Furthermore, dietary glucosylceramide improves skin function (Kawada et al. 2013; Duan et al. 2012; Tsuji et al. 2006; Miyazaki et al. 2005). Alteration of intestinal microbiota, as found in this study, might be the cause of these observed phenomena.

**Conclusion**

In conclusion, we have elucidated that the Japanese dietary fungus koji A. oryzae functions as a prebiotic, since glycosylceramide contained in koji (rice fermented with Aspergillus oryzae) increases B. coccoides in the intestine. This knowledge might be a novel link between Japanese cuisine and Japanese longevity.

**Authors’ contributions**

HK, TY, and KN designed the whole research. HH, HM, AF, and TS extracted and purified the lipids. SM analyzed the metabolism of glycosylceramide. JN analyzed the genome of the intestinal microbial flora. HH analyzed the constitution of the intestinal microbial flora. HK and HH wrote the manuscript. All authors read and approved the final manuscript.

**Author details**

1 Department of Environmental Science, Faculty of Agriculture, Saga University, Honjo-cho, Saga City, Saga, Japan. 2 Department of Applied Biochemistry and Food Science, Faculty of Agriculture, Saga University, Honjo-cho, Saga City, Saga, Japan. 3 Department of Applied Biochemistry and Food Science, Faculty of Agriculture, Saga University, Honjo-cho, Saga City, Saga, Japan. 4 Department of Biochemistry and Biotechnology, Faculty of Agriculture, Kyushu University, Higashiku, Fukuoka, Japan.

**Acknowledgements**

We acknowledge Professor Katsuhiko Kitamoto at Nihon Pharmaceutical University for critical advice regarding the historical role of koji Aspergillus.

**Competing interests**

The authors declare that they have no competing interests.

**Funding**

This work was supported by JSPS Grant-in-Aid for Scientific Research (C) Grant Number 15K07363 (to H. K.).

**Received:** 24 May 2016 **Accepted:** 29 July 2016

**Published online:** 11 August 2016

**References**

Arai K, Mizobuchi Y, Tokui Y, Aida K, Yamashita S, Ohnishi M, Kinoshita M (2015) Effects of dietary plant-origin glucosylceramide on bowel inflammation in DSS-treated mice. J Oleo Sci 64:737–742

Bajaj JS, Hylemon PB, Ridlon JM, Heuman DM, Daita K, White MB, Monteth P, Noble NA, Sikaroodi M, Gillevet PM (2012) Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol 303:G675–G685

Benakis C, Brea D, Caballero S, Faraco G, Moore J, Murphy M, Sita G, Rachumi G, Ling L, Palmer CG, Iadeola C, Anrather J (2016) Commensal microbiota affects ischemic stroke outcome by regulating intestinal γδ T cells. Nat Med 22:516–523. doi:10.1038/nm.4068

Brown GD, Gordon S (2001) Immune recognition. A new receptor for beta-glucans. Nature 413:36–37

Chen W, Liu F, Ling Z, Tong X, Xiang C (2012) Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer. PLoS ONE 7:e39743. doi:10.1371/journal.pone.0039743

De Filippo C, Cavaliere D, Di Paola M, Ramazzotti M, Poullet JB, Massart S, Collini S, Pieraccini G, Lionetti P (2010) Impact of diet in shaping gut microbiota
revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci USA 107:14691–14696

Del Chierco F, Nobilivernocchi P, Russo A, De Stefani G, Giani D, Furlanello C, Zandonà A, Paci P, Capuani G, Dallapiccola B, Micchelli A, Alisi A, Putignani L (2010) Gut microbiota profiling of pediatric NAFLD and obese patients unveiled by an integrated meta-omics based approach. Hepatology. doi: 10.1002/hep.28572

Duan J, Sugawara T, Hirose M, Aida K, Sakai S, Fuji A, Hirata T (2012) Dietary sphingolipids improve skin barrier functions via the upregulation of ceramide synthases in the epidermis. Exp Dermatol 21:448–452

Fletcher MJ (1968) A colorimetric method for estimating serum triglycerides. Clin Chem Acta 22:393–397

Folch J, Lees M, Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226(1):497–509

Furuya H, Ide Y, Hamamoto M, Asanuma N, Hino T (2010) Isolation of a novel Bifidobacteria strain from human faeces. Int J Clin Oncol 16:133–140

Ishibashi K, Miura NN, Adachi Y, Tamura H, Tanaka S, Ohno N (2004) The stabilization and biological activities of Aspergillus beta-(1->3) glucan. FEMS Immunol Med Microbiol 42:155–166

Kakiyama G, Pandak WM, Gillevet PM, Hylemon PB, Heuman DM, Daita K, Takei M, Mitsutake S, Kitagaki K (2016) Chemical analysis of the sugar moiety of sphingolipids improve skin barrier functions via the upregulation of sphingolipid synthases in the epidermis. Exp Dermatol 21:448–452

Kurakawa T, Ogata K, Matsuda K, Tsuji H, Kubota H, Takada T, Kado Y, Kusumoto K, Arima T, Akita O, Kashiwagi Y, Moro A, Ichinose S, Omori A, Iida H, Nakamura T, Tho M (2001) Purification, characterization, molecular cloning, and subcellular distribution of neutral ceramidase of rat kidney. J Biol Chem 276:26249–26259

Miyashita K, Shinomi N, Shirai H, Domb M, Kimita H (2005) Reduction of transepidermal water loss by oral intake of glucosylceramides in patients with atopic eczema. Allergy 60:1454–1455

Morrison J, Peeters M, Hahn BH, Ochman H (2014) The gut microbiome during human evolution. Proc Natl Acad Sci USA 111:16431–16435

Mukamoli H (1985) Eosinophilic gastroenteritis. Clin Radiol 36:220–225

Nepelska M, Leteche F, Doné J, Blottière HM (2011) Identification of NF-κB modulations capabilities within human intestinal commensal bacteria. J Biomed Biotechnol. doi:10.1155/2011/282356

Lu C, Finegold SM, Song Y, Lawson PA (2008) Reclassification of Clostridium cocoides, Ruminococcus hansenii, Ruminococcus hydrogenotrophicus, Ruminococcus luti, Ruminococcus productus and Ruminococcus shikini as Blautia cocoides gen. nov., comb. nov., Blautia hansenii comb. nov., Blautia luti comb. nov., Blautia producta comb. nov., Blautia shikini comb. nov. and description of Blautia wexlerae sp. nov., isolated from human faeces. Int J Syst Evol Microbiol 58:1896–1902

Nilsen A (1969) Metabolism of cerebroside in the intestinal tract of the rat. Biochim Biophys Acta 187:113–121

Nishijima S, Suda W, Oshima K, Kim SW, Hirose Y, Morita H, Hattori M (2016) The gut microbiota of healthy Japanese and its microbial and functional uniqueness. DNA Res 23:125–133

Park SK, Kim MS, Bae JW (2013) Blautia faecis sp. nov., isolated from human faeces. Int J Syst Evol Microbiol 63:599–603

Rajilić-Stojanović M, Biagi E, Heilig H, Kajander K, Kekkonen RA, Tims S, de Vos WM (2011) Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 141:1792–1801

Reagan-Shaw S, Nihal M, Ahmad N (2008) Dose translation from animal to human studies revisited. FASEB J 22:659–661

Rousset G, Siakotos AN, Fleisher S (1996) Quantitative analysis of phospholipids by thin-layer chromatography and phosphorus analysis of spots. Lipids 1(1):85–86
Russo SB, Ross JS, Cowart LA (2013) Sphingolipids in obesity, type 2 diabetes, and metabolic disease. Handb Exp Pharmacol 216:373–401

Sawada K, Sato T, Hamajima H, Jayakody LN, Hirata M, Yamashiro M, Tajima M, Mitsutake S, Nagao K, Tsuge K, Abe F, Hanada K, Kitagaki H (2015) Glucosylceramide contained in koji mold-cultured cereal confers membrane and flavor modification and stress tolerance to Saccharomyces cerevisiae during coculture fermentation. Appl Environ Microbiol 81:3688–3698

Schmelz EM, Crall KJ, Larocque R, Dillehay DL, Merrill AH Jr (1994) Uptake and metabolism of sphingolipids in isolated intestinal loops of mice. J Nutr 124(5):702–712

Shirouchi B, Nagao K, Inoue N, Ohkubo T, Hibino H, Yanagita T (2007) Effect of dietary omega 3 phosphatidylcholine on obesity-related disorders in obese Otsuka Long-Evans Tokushima Fatty rats. J Agric Food Chem 55:7170–7176

Sommer F, Bäckhed F (2013) The gut microbiota—masters of host development and physiology. Nat Rev Microbiol 11:227–238

Sperry WM, Webb M (1950) A revision of the Schoenheimer–Sperry method for cholesterol determination. J Biol Chem 187:97–106

Suchodolski JS, Markel ME, Garcia-Mazcorro JF, Unterer S, Heilman RM, Dowd SE, Kachroo P, Ivanov I, Minamoto Y, Dilleman EM, Steiner JM, Cook AK, Toresson L (2012) The fecal microbiome in dogs with acute diarrhea and idiopathic inflammatory bowel disease. PLoS ONE. doi:10.1371/journal.pone.0051907

Symolon H, Schmelz EM, Dillehay DL, Merrill AH Jr (2004) Dietary soy sphingolipids suppress tumorigenesis and gene expression in 1,2-dimethylhydrazine-treated CF1 mice and ApcMin/+ mice. J Nutr 134(5):1157–1161

Takahashi K, Izumi K, Nakahata E, Hirata M, Sawada K, Tsuge K, Nagao K, Kitagaki H (2014) Quantitation and structural determination of glucosylceramides contained in sake lees. J Oleo Sci 63:15–23

Truman JP, García-Barros M, Obeid LM, Hannun YA (2014) Evolving concepts in cancer therapy through targeting sphingolipid metabolism. Biochim Biophys Acta 1841:1174–1188

Tsuji K, Mitsutake S, Ishikawa J, Takagi Y, Akiyama M, Shimizu H, Tomiyama T, Igarashi Y (2006) Dietary glucosylceramide improves skin barrier function in hairless mice. J Dermatol Sci 44:101–107

Tuvonen E, Keto J, Nikkilä J, Mattila J, Lähdeemäki K (2013) Cytokine response of human mononuclear cells induced by intestinal Clostridium species. Anaerobe 19:70–76

United Nations Educational, Scientific and Cultural Organization (2013) Washoku, Traditional dietary cultures of the Japanese, notably for the celebration of New Year. http://www.unesco.org/culture/ich/index.php?lg=en&pg=00011&RL=00869. Accessed 15 May 2016

Wang Y, Harding SV, Eck P, Thandapilly SJ, Gamel TH, Abdel-Aal-EM Crow GH, Tosh SM, Jones PJ, Ames NP (2016) High-molecular-weight β-glucan decreases serum cholesterol differentially based on the CYP7A1 rs3808767 polymorphism in mildly hypercholesterolemic adults. J Nutr 146:720–727

Yamamoto K, Hatakeyama Y, Sakamoto Y, Honma T, Jibu Y, Kawakami Y, Tsuduki T (2016) The Japanese diet from 1975 delays senescence and prolongs life span in SAMPI mice. Nutrition 32:122–128

Yazama H, Kitatani K, Fujivara K, Kato M, Hashimoto-Nishimura M, Kawamoto K, Hasegawa K, Kitano H, Bielawska A, Bielawski J, Okazaki T (2015) Dietary glucosylceramides suppress tumor growth in a mouse xenograft model of head and neck squamous cell carcinoma by the inhibition of angiogenesis through an increase in ceramide. Int J Clin Oncol 20:438–446

Yunoki K, Ogawa T, Ono J, Miyashita R, Aida K, Oda Y, Onishi M (2008) Analysis of sphingolipid classes and their contents in meals. Biosci Biotechnol Biochem 72:222–225